Mechanisms by Which Pharmacotherapy May Impact Cancer Risk among Individuals with Overweight and Obesity DOI Open Access

Edward R. Sauter,

Tanya Agurs‐Collins

Cancers, Journal Year: 2024, Volume and Issue: 16(19), P. 3275 - 3275

Published: Sept. 26, 2024

Diets geared to reduce cancer risk in overweight and obese individuals focus on (1) caloric restriction (every day, some days, or most hours of each day); (2) changes macronutrient intake; (3) a combination the prior two strategies. generally fail because nonadherence due limited sustained weight loss. This is contrast diet supplemented with loss medication, so long as participant continues medication after bariatric surgery, which adherence tends be much higher. Among who regain medications are proving beneficial maintaining Both maximum essential for all forms effective metabolic improvement, including reduction. The this report assess state research consequence pharmacotherapy use proposed loss-independent effects subsequent reduction, potential role conjunction (bariatric) surgery (MBS). Finally, we present Notices Funding Opportunities (NOFOs) by National Cancer Institute (NCI) better understand mechanism(s) that driving efficacy

Language: Английский

Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists DOI Open Access
Alla A. Boshchenko, Л. Н. Маслов, А. V. Mukhomedzyanov

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(9), P. 4900 - 4900

Published: April 30, 2024

The high mortality rate among patients with acute myocardial infarction (AMI) is one of the main problems modern cardiology. It quite obvious that there an urgent need to create more effective drugs for treatment AMI than those currently used in clinic. Such could be enzyme-resistant peptide analogs glucagon-like peptide-1 (GLP-1). GLP-1 receptor (GLP1R) agonists can prevent ischemia/reperfusion (I/R) cardiac injury. In addition, chronic administration GLP1R alleviate development adverse remodeling infarction, hypertension, and diabetes mellitus. protect heart against oxidative stress reduce proinflammatory cytokine (IL-1β, TNF-α, IL-6, MCP-1) expression myocardium. stimulation inhibits apoptosis, necroptosis, pyroptosis, ferroptosis cardiomyocytes. activation augments autophagy mitophagy downregulate reactive species generation through Epac GLP1R/PI3K/Akt/survivin pathway. GLP1R, kinases (PKCε, PKA, Akt, AMPK, PI3K, ERK1/2, mTOR, GSK-3β, PKG, MEK1/2, MKK3), enzymes (HO-1 eNOS), transcription factors (STAT3, CREB, Nrf2, FoxO3), KATP channel opening, MPT pore closing are involved cardioprotective effect agonists.

Language: Английский

Citations

13
Decreased Risk of Readmission and Complications With Preoperative GLP-1 Analog Use in Patients Undergoing Primary Total Joint Arthroplasty DOI
Anirudh Buddhiraju, Whitney Kagabo, Harpal S. Khanuja

et al.

The Journal of Arthroplasty, Journal Year: 2024, Volume and Issue: 39(12), P. 2911 - 2915.e1

Published: May 31, 2024

Language: Английский

Citations

10
Safety and effectiveness in an uncontrolled setting of glucagon‐like‐peptide‐1 receptor agonists in patients with familial partial lipodystrophy: Real‐life experience from a national reference network DOI Creative Commons

Sophie Lamothe,

I. Belalem,

Marie‐Christine Vantyghem

et al.

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 20, 2025

Abstract Aim To describe the effects of Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) in patients with familial partial lipodystrophy (FPLD) assessed a real‐life setting national reference network. Patients and Methods We retrospectively collected clinical metabolic parameters FPLD French network, who initiated GLP‐1RA. Data were recorded before, at one‐year (12 ± 6 months) latest follow‐up on GLP‐1RA therapy (≥18 months). Results Seventy‐six (89.4% women), diagnosed LMNA ‐related FPLD2 ( n = 57), PPARG FPLD3 4), PLIN1 FPLD4 5) or FPLD1 10) between 2008 2024. aged median (IQR) 48 years (34.5–57), body mass index (BMI) was 26.0 kg/m 2 (23.9–29.5), HbA1c 8.3% (7.5–9.3), triglycerides 2.31 mmol/L (1.62–3.88). used addition to previously antidiabetics, 50% being insulin‐treated. After one year therapy, BMI, significantly decreased 25.6 (22.7–29.1), 7.3% (6.6–8.3) 1.97 (1.5–3.2) respectively p < 0.001, 0.001 0.01, respectively), without significant changes other antidiabetic lipid‐lowering drugs. Gamma‐glutamyl‐transferase alanine‐aminotransferase levels also decreased. Effects HbA1c, BMI persisted long term. One case acute pancreatitis occurred during follow‐up, associated severe hypertriglyceridemia non‐observant patient. Gastrointestinal symptoms affected 34% patients, leading withdrawal six patients. Conclusion improved large majority FPLD. Larger prospective controlled studies are warranted for identification predictive factors safety.

Language: Английский

Citations

1
Anti-obesity and gut microbiota modulation effects of chondroitin sulfate on obese mice induced by high-fat diet DOI

Qingshan Shen,

Xudong Qi,

Yilin Liu

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 298, P. 139968 - 139968

Published: Jan. 16, 2025

Language: Английский

Citations

0
Trends, Demographics, and Outcomes for Glucagon-Like Peptide-1 Receptor Agonist Use in Total Knee Arthroplasty: An 11-Year Perspective DOI
Jonathan Katzman, Muhammad Ammar Haider, Casey Cardillo

et al.

The Journal of Arthroplasty, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects DOI Creative Commons

Robert F. Kushner,

Odd Erik Johansen, Krysmarú Araujo Torres

et al.

Obesities, Journal Year: 2025, Volume and Issue: 5(2), P. 29 - 29

Published: April 24, 2025

Background/Objectives: Obesity is a chronic, progressive, recurrent disease associated with impaired health, affecting an increasing proportion of the population worldwide. Newer-generation incretin-based therapies (IBTs) (liraglutide, semaglutide, and tirzepatide) have shown greater efficacy than older anti-obesity medications. This systematic literature review provides overview evidence on symptomatic adverse events (AEs) patient-reported outcomes IBTs to facilitate clinical decision-making. Methods: A search was conducted using predefined strategy identify controlled trials real-world (RWE) studies assessing IBTs. Results: Among 4414 publications identified, 81 (>400,000 participants) were included. Liraglutide (n = 49), semaglutide 34), tirzepatide 7) used in 48 33 RWE studies. Gastrointestinal (GI) AEs most common: placebo-subtracted incidences 5–39% for nausea, −7–39% diarrhea, 2–31% constipation, 0–26% vomiting, 2–20% abdominal pain, no clear difference across Most mild or moderate mainly occurred during dose escalation. Quality life reported 27 generally showed improvements Conclusions: study confirms that GI are common Clinicians should keep AE profile mind consider where additional preventative measures may be required.

Language: Английский

Citations

0
A Brief Review of Incretin Mimetics Intended for the Management of Diabetes and Associated Comorbidities DOI Open Access

Faryal Haider,

Syed Sarim Imam,

Orien L. Tulp

et al.

Published: May 21, 2024

Abstract Incretin mimetics, also known as glucagon-like peptide-1 (GLP-1) receptor agonists, are a class of medications used to treat type 2 diabetes by mimicking the actions incretin hormones in body. These responsible for promoting insulin release from pancreas response nutrient intake, well decreasing glucagon secretion, slowing gastric emptying, and satiety. By imitating these actions, mimetics help regulate blood sugar levels individuals with glucose intolerance. One key benefits is its ability lower without causing hypoglycemia. This especially important who may experience dangerous drops when using other medications. Additionally, have been shown promote weight loss some individuals, making them valuable option those struggling obesity addition diabetes. administered injection, once or twice daily, depending on specific medication. They often combined medications, such metformin insulin, optimal control. generally well-tolerated, common side effects including nausea, vomiting, diarrhea, which usually diminish over time body adjusts Studies that can improve cardiovascular outcomes diabetes, reducing risk heart attacks strokes. particularly significant given increased disease preserve pancreatic beta-cell function, producing insulin. slow progression reduce need higher doses time. Despite their many benefits, not limitations. be expensive compared make less accessible individuals. there concerns about potential pancreatitis cancer associated use However, more research needed fully understand risks. It healthcare providers carefully assess each individual's unique needs medical history considering mimetics. appropriate everyone, cancer. Patients should educated medications' proper administration ensure safety efficacy. Overall, emerged an therapeutic offering mechanism action control, loss, risk. With ongoing development this field, continue show promise tools managing complications comorbidities.

Language: Английский

Citations

3
SIBUTRAMINA E LIRAGLUTIDA NA TERAPÊUTICA DA OBESIDADE DOI Creative Commons

Jaianny Chaves Braga,

Laura Alves de Aguiar Glória Barbosa,

Samyra Giarola Cecílio

et al.

Revista Contemporânea, Journal Year: 2024, Volume and Issue: 4(4), P. e4034 - e4034

Published: April 22, 2024

A obesidade, uma condição crônica global, demanda abordagens multifatoriais para seu tratamento eficaz. Este estudo avalia o uso da sibutramina e liraglutida, destacando-se a necessidade de escolha criteriosa baseada nos perfis risco benefício cada paciente. Conclusões apontam eficácia desses medicamentos na perda peso, enfatizando importância considerar individualmente os riscos associados.

Citations

0
Mechanisms by Which Pharmacotherapy May Impact Cancer Risk among Individuals with Overweight and Obesity DOI Open Access

Edward R. Sauter,

Tanya Agurs‐Collins

Cancers, Journal Year: 2024, Volume and Issue: 16(19), P. 3275 - 3275

Published: Sept. 26, 2024

Diets geared to reduce cancer risk in overweight and obese individuals focus on (1) caloric restriction (every day, some days, or most hours of each day); (2) changes macronutrient intake; (3) a combination the prior two strategies. generally fail because nonadherence due limited sustained weight loss. This is contrast diet supplemented with loss medication, so long as participant continues medication after bariatric surgery, which adherence tends be much higher. Among who regain medications are proving beneficial maintaining Both maximum essential for all forms effective metabolic improvement, including reduction. The this report assess state research consequence pharmacotherapy use proposed loss-independent effects subsequent reduction, potential role conjunction (bariatric) surgery (MBS). Finally, we present Notices Funding Opportunities (NOFOs) by National Cancer Institute (NCI) better understand mechanism(s) that driving efficacy

Language: Английский

Citations

0